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of insulin resistance but are also associated with the microvascular and macrovascular complications tra-
ditionally linked to diabetes. They predict an increased risk for death and morbidity due to cardiovascular
disease.
There is growing evidence that early detection of this state of ‘‘pre-diabetes” enables us to limit these
recognized complications and perhaps to halt the progression to diabetes. For all pre-diabetes patients’
life style modiﬁcations, emphasizing modest weight loss & moderate physical activity are strongly rec-
ommended. Pharmacological intervention may also be necessary. Many studies have shown several
drugs, both antidiabetic and nonhypoglycemic agents to be useful. If pharmacological treatment is
required, Metformin is considered the ﬁrst choice because of its safety, tolerability, efﬁcacy and low
cost.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Diabetes and its complications are a growing concern world-
wide. It has become an epidemic menace in most developed
and many developing countries. Globally, the number of people
with diabetes is expected to almost double in the next two
decades, increasing from 194 million in 2003 to 380 million in
2025 [1]. The associated morbidity, mortality and high costs of
health care, made type 2 diabetes an important global public
health challenge and target for prevention. In Jordan, it was esti-
mated that the total treatment costs (direct and indirect) incurred
in regards to diabetes was 1,308 Billion JD per year [2], an enor-
mous public health burden, and made the prevention of diabetes
a critical health goal.
Progression to overt diabetes from a pre-diabetic state occurs
gradually, over a period of many years; however, current estimates
indicate that most individuals (perhaps up to 70%) with pre-dia-
betic state eventually develop diabetes [3–5]. Studies have shown
that patients during the pre-diabetic state are at increased risk of
microvascular (retinopathy, nephropathy and neuropathy) and
macrovascular (cardiovascular disease and stroke) complications
and thus have higher morbidity and mortality than individuals
with normal glucose homeostasis [6].ellitus. Published by Elsevier Ltd. O
: +962 6 535 33 76.Between 1997 and 2006, eight major clinical trials examined
whether lifestyle or pharmacologic interventions would prevent
or delay the development of diabetes in populations with IFG
and/or IGT [4,5,7,12]. All of these trials demonstrated a reduction
in the development of diabetes of 25–60% over the period of fol-
low-up depending on the type of intervention applied [8–11].2. Deﬁnition of pre-diabetes and its natural history
The ADA deﬁnes normal glucose tolerance as a FPG < 100 mg/dl
and 2 h PG in response to a 75 g OGTT of <140 mg/dl [13]. Diabetes
is deﬁned as a FPGP 126 mg/dl or a 2 h PGP 200 mg/dl during an
OGTT. IFG and IGT represent intermediate states of abnormal glu-
cose regulation that exist between normal glucose homeostasis
and diabetes. It is a state of heightened risk of developing type 2
diabetes and other associated complications.
Two different categories of pre-diabetes exist: IFG which is de-
ﬁned by an elevated fasting plasma glucose (FPG) concentration
(P100 and <126 mg/dl) [14] and IGT which is deﬁned by an ele-
vated 2-h plasma glucose concentration (P140 and <200 mg/dl)
after a 75-g glucose load on the oral glucose tolerance test (OGTT)
in the presence of an FPG concentration <126 mg/dl [14].
Studies have shown that an oral glucose tolerance test (OGTT) is
a more sensitive measure of early abnormalities in glucose regula-
tion than fasting plasma glucose or HbA1c [6]. This is possibly due
to the fact that IGT is a consequence of two processes that arepen access under CC BY-NC-ND license.
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glycemia: insulin resistance and dyslipidemia [15]. In obesity, as
skeletal muscles lose sensitivity to insulin, more glucose is taken
up by adipocytes, stimulating the production and release of more
free fatty acids (FFAs) and triglycerides (TG). Elevated circulating
FFAs in turn promote hyperglycemia by stimulating hepatic
gluconeogenesis while inhibiting insulin-mediated glucose uptake
and storage as glycogen.
The prevalence of IFG and IGT varies considerably among differ-
ent ethnic groups. Data also indicate that the prevalence of IFG and
IGT is 26% and 15% respectively [16]. Also in Jordan Ajlouni et al re-
ported the prevalence of pre-diabetes (IFG and IGT) to be 10% in
1997 [17]and the prevalence of IFG to be 7.8% in 2004 [18]. The
prevalence of IFG and IGT also differs by age and sex, being more
common in women than in men and increasing with advancing
age [19].
The course of pre-diabetes (both IGT and IFG) is variable and
difﬁcult to predict. The different rates of progression reﬂect differ-
ent genetic and environmental factors. Furthermore, patients with
both IGT and IFG develop diabetes twice the rate as do individuals
who manifest a single abnormality [20]. Patients with a higher FPG
(i.e. 6.1–6.9 mmol/L [110–125 mg/dL]) are also at much higher risk
of progression to diabetes than those with lower (but abnormal)
FPG levels (5.6–6.0 mmol/L [100–109 mg/dL]) [4].3. Pathogenesis of IFG and IGT
The basic patho-physiological mechanisms underlying pre-dia-
betes are insulin resistance and defective insulin secretion. How-
ever, IFG and IGT differ in the nature of both of these defects [21].
In isolated IFG, there is a predominant hepatic insulin resistance
with relatively preserved skeletal muscle sensitivity to insulin. On
the other hand, in isolated IGT the hepatic insulin sensitivity is nor-
mal to slightly reduced and the resistance of skeletal muscles to
insulin is moderate to severe.
IFG and IGT also differ in their pattern of impairment of insulin
secretion. In isolated IFG there is a decrease in the ﬁrst-phase (0–
10 min) insulin secretory response to intravenous glucose and a re-
duced early-phase (ﬁrst 30 min) insulin response to oral glucose
but the late-phase (60–120 min) plasma insulin response during
the OGTT is normal. In isolated IGT there is a defect in both early
and late-phase insulin secretion.4. Microvascular complications of prediabetes
Classically diabetes is associated with microvascular and mac-
rovascular complications but growing evidence shows that thesecomplications are also present in the pre-diabetic state and that
their risk increases with the distribution of blood glucose concen-
tration well below the overt diabetes. The Aus Diab studies, for
example, which is a population-based survey of 11,247 adults
aged over 25 years found that 21.7% of individuals with pre-dia-
betes (IGT and/or IFG) had at least one microvascular complica-
tion [22].
In a cross-sectional study, neuropathy was found in 26% of 279
patients with diabetes, 11.2% of 89 patients with IGT, and only 3.9%
of 577 age-matched normal control subjects [23]. IGT associated
neuropathy is a symmetric, distal sensory polyneuropathy with
prominent neuropathic pain which is phenotypically similar to dia-
betic neuropathy [24,25]. This reﬂects similar ﬁber loss and altered
nerve morphology in both IGT and diabetes. Autonomic dysfunc-
tion manifested mainly as vagal dysautonomia (abnormal heart
rate recovery following exercise, blunted R–R interval variability
to deep breathing, and reduced expiration to inspiration ratio) is
also prevalent in pre-diabetes [26].
Microalbuminuria also has an increased prevalence in IGT. A
very large population based study in China [27] demonstrated that
the rate of albumin excretion was signiﬁcantly higher among IGT
subjects compared with the non-diabetic control group (7.2 ± 5.7
vs. 4.5 ± 2.8).
Independent studies have noted an approximate fourfold in-
crease in the prevalence of retinopathy among Pima Indians
with IGT compared with age-matched control subjects [28]. Data
suggest that the ﬁrst stage of retinal injury occurs during IGT
[28].5. Macrovascular complications of prediabetes
A diagnosis of pre-diabetes not only identiﬁes subjects who are
at increased risk of diabetes but also at risk of cardiovascular and
other macrovascular complications of diabetes. Data have shown
that IGT patients are at greater risk of death from all causes and
have a two to ﬁvefold increased incidence of new-onset cardiovas-
cular ischemia, fatal and total myocardial infarction, and stroke in
comparison with their age-matched normoglycemic control sub-
jects [29,30]. The Paris prospective study [31] has shown during
the ten year follow up period that subjects with impaired glucose
tolerance have about 50% increased risk of cardiovascular mortal-
ity. Other studies have shown an increased incidence of heart fail-
ure and coronary artery disease in patients with IGT irrespective of
progression to diabetes [32,33].
While some studies have shown that both IGT and IFG confer an
increased risk of cardiovascular disease [34], others, like the Funag-
ata diabetes study, suggest that IGT is more strongly associated
with cardiovascular disease risk than with fasting hyperglycemia
[29].6. Rationale for the prevention of diabetes and
recommendations for clinical management
The considerable increase in the incidence of diabetes and its
serious long term complications strongly support efforts to pre-
vent or delay its occurrence. This is the rationale behind the con-
sensus statement for the management of patients with pre-
diabetes released by the ADA in October, 2006. The panel con-
cluded that intervention was warranted, based on the expecta-
tion that delay of diabetes would postpone the requirement for
complicated treatment regimens and that microvascular compli-
cations (and potentially CVD) would be delayed or prevented
[13].
Fortuitously, a wide variety of interventions have been shown
to alter the natural course of IFG and IGT and their progression
Table 1
Diabetes prevention program.
Cumulative incidence of diabetes (%) P-value
Metformin ; 31% <0.001
Lifestyle ; 58% <0.001
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other similar large well-designed prospective studies make it clear
that aggressive modiﬁcation of diet and exercise can prevent or
slow the progression from IGT to diabetes [4]. In the Diabetes Pre-
vention Program (DPP), diet and exercise modiﬁcation was signif-
icantly more effective in diabetes risk reduction than
pharmacological glucose reduction with Metformin [4] (Table 1).
Diet and exercise were also more effective than Metformin in
returning IGT subjects to a normal glucose tolerance.
Since intensive lifestyle intervention provides the greatest
reduction in the occurrence of diabetes, along with a modest
reduction in CVD risk factors, patients with IGT should be referred
to a nutritionist for counseling on exercise and diet with the goal of
losing 5–7% of body weight and increasing moderate aerobic exer-
cise to 150 min weekly (the DPP goals) [4] which is the treatment
of choice for patients with prediabetes.
Because lifestyle modiﬁcation is usually difﬁcult to maintain,
pharmacological interventions have been studied to prevent the
progression to type 2 diabetes. Several oral antidiabetic agents
have been shown to be effective at delaying onset of type 2 diabe-
tes. Thiazolidinediones (TZDs) reduced incidence of diabetes by
60% (PIPOD and DREAM trials) [35,36], whilst Metformin (in
DPP) [4], Acarbose (in STOP-NIDDM study) [36] and Orlistat (in
XENDOS study) [12] are only about half as effective as the TZDs.
But the beneﬁts of treatment still need to be balanced against
the safety and tolerability of the intervention. If pharmacological
treatment is warranted, metformin should be considered ﬁrst be-
cause of its favourable overall safety, tolerability, efﬁcacy, and cost
proﬁle.
Finally, drugs that do not primarily target hyperglycemia may
also reduce the risk for type 2 diabetes. A large number of trials
of ACE-inhibitors or ARBs for various CV indications suggest that
these drugs could reduce risk for type 2 diabetes by as much as
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